Skip to main
PSNL

Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc (PSNL) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 0%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Personalis is well-positioned for growth as they continue to expand their commercial team and clinical trial offerings. Their focus on breast cancer and other cancers and strong demand for their MRD test are key drivers of their future revenue goals. The company's solid financial position and strategic partnerships with industry leaders also provide a strong foundation for success and potential further expansion in the oncology market.

Bears say

Personalis is facing volatility in budgets and ordering patterns from pharma companies and is relying heavily on its NeXT Personal MRD test to drive higher levels of growth. However, there is uncertainty and risk associated with obtaining Medicare coverage for this test and achieving market penetration. Additionally, the company has incurred significant losses and may struggle to achieve profitability, and its success is heavily dependent on its commercial partner Tempus.

Personalis Inc (PSNL) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 0% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Personalis Inc (PSNL) Forecast

Analysts have given Personalis Inc (PSNL) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Personalis Inc (PSNL) has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Personalis Inc (PSNL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.